modelThiotepa_1

Diagram of Thiotepa_1

Extends from Pharmacolibrary.Drugs.ATC.L.L01AC01_1.

Information

name:Thiotepa_1
ATC code:L01AC01_1
route:intravenous
compartments:2
dosage:200mg
volume of distribution:1.56L
clearance:31mL/min/kg
other parameters in model implementation

Thiotepa is an alkylating agent of the ethyleneimine type, used primarily as an antineoplastic chemotherapy drug. It has been indicated for use in the treatment of various cancers including breast cancer, ovarian cancer, and bladder cancer. Thiotepa is approved for use as a conditioning treatment prior to hematopoietic stem cell transplantation and for high-dose chemotherapy settings.

Pharmacokinetics

Pharmacokinetic parameters reported for pediatric patients undergoing stem cell transplantation using intravenous thiotepa.

References

  1. de Jonge, ME, et al., & Beijnen, JH (2005). Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin. Therapeutic drug monitoring 27(6) 756–765. DOI:10.1097/01.ftd.0000177224.19294.92 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16306851

  2. Huitema, AD, et al., & Beijnen, JH (2000). Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods. Clinical pharmacology and therapeutics 67(6) 621–630. DOI:10.1067/mcp.2000.106827 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10872644

  3. van Warmerdam, LJ, et al., & Beijnen, JH (1994). Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination. Cancer chemotherapy and pharmacology 35(2) 179–181. DOI:10.1007/BF00686644 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7987998

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)